Shanghai Institute of Pharmaceutical Industry

Cspc Zhonggi Pharmaceutical Technology (shijiazhuang) Co. Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Zhijie Weng

Jianqi Li

Yongyong Zheng

Hua Jin

Liying Huang

Na Lv

Chunnian Zhang

Yang Min

The invention discloses 1-butyl-2-hydroxyl aralkyl piperazine derivatives and their use as antidepressants. The derivatives of the present invention have triple inhibition effect on the reuptake of 5-HT, NA and DA, and can be administrated to the patients in need thereof in form of composition by route of oral administration, injection and the like. Compared with clinically currently used dual targets antidepressants (such as venlafaxine), said derivatives may have stronger antidepression effect, broader indications, faster onset and lower neurotoxicity and side reaction; and said derivatives have stronger antidepression activity, lower toxicity, higher bioavailability, longer half life and better druggablity, compared with aryl alkanol piperazine derivatives and optical isomers thereof disclosed in prior art. The 1-butyl-2-hydroxyl aralkyl piperazine derivative is the free alkali or its salt of a compound of formula below: 

1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof

Aralkyl formyl alkyl piperazine derivatives Pharmaceutical compositions comprising the same, and methods of using them as a neuroprotective agent. Pharmaceutical results indicate that these compounds have excellent neuroprotective activities and fewer side effects.

Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent

Growing community of inventors

Shanghai, China

Zhijie Weng